Stay updated with breaking news from Michael Vi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Merck's (MRK) Q2 sales grew 28% Y/Y on the back of COVID therapy Lagevrio and blockbuster cancer drug Keytruda while also raising and narrowing its FY22 outlook.Q2 total sales grew...
Merck's (MRK) blockbuster drug Keytruda did not meet the main goal of event-free survival ((EFS)) in a phase 3 trial in patients with w type of head and neck cancer.The...
Palantir stock has outperformed the market since we published our previous Buy rating. Read why the market has priced in a recessionary scenario for PLTR.
Naspers' plan creates a lot of uncertainty for Tencent's (TCEHY) stock as the share sales could go on for years. Click here to know more...
LendingClub trades at 7-8x 2022 earnings, despite a clear path to grow earnings by double digits. Click here to read more about this long-term growth stock.